Factors associated with uMRD in the peripheral blood or bone marrow at study entry
| Variable . | n . | Association with PB/BM uMRD attainment . | ||
|---|---|---|---|---|
| Cause-specific HR (95%CI) . | P . | |||
| Age ≥65 y | Y | 38 | 1.28 (0.57-2.87) | .558 |
| N | 24 | |||
| ≥4 prior lines of therapy | Y | 25 | 0.59 (0.24-1.44) | .240 |
| N | 37 | |||
| Fludarabine refractory | Y | 30 | 0.68 (0.29-1.57) | .359 |
| N | 32 | |||
| Bulky disease (>5 cm) | Y | 28 | 1.14 (0.50-2.61) | .752 |
| N | 34 | |||
| Rituximab combination therapy | Y | 14 | 2.86 (1.22-6.69) | .012 |
| N | 48 | |||
| Dose ≥400 mg | Y | 43 | 1.03 (0.43 – 2.47) | .947 |
| N | 19 | |||
| Del(17p) and/or TP53 mutation | Y | 34 | 0.58 (0.26-1.33) | .192 |
| N | 24 | |||
| Complex karyotype | Y | 15 | 0.58 (0.19-1.73) | .320 |
| N | 27 | |||
| Prior navitoclax | Y | 9 | 0.210 (0.03-1.59) | .095 |
| N | 53 | |||
| Variable . | n . | Association with PB/BM uMRD attainment . | ||
|---|---|---|---|---|
| Cause-specific HR (95%CI) . | P . | |||
| Age ≥65 y | Y | 38 | 1.28 (0.57-2.87) | .558 |
| N | 24 | |||
| ≥4 prior lines of therapy | Y | 25 | 0.59 (0.24-1.44) | .240 |
| N | 37 | |||
| Fludarabine refractory | Y | 30 | 0.68 (0.29-1.57) | .359 |
| N | 32 | |||
| Bulky disease (>5 cm) | Y | 28 | 1.14 (0.50-2.61) | .752 |
| N | 34 | |||
| Rituximab combination therapy | Y | 14 | 2.86 (1.22-6.69) | .012 |
| N | 48 | |||
| Dose ≥400 mg | Y | 43 | 1.03 (0.43 – 2.47) | .947 |
| N | 19 | |||
| Del(17p) and/or TP53 mutation | Y | 34 | 0.58 (0.26-1.33) | .192 |
| N | 24 | |||
| Complex karyotype | Y | 15 | 0.58 (0.19-1.73) | .320 |
| N | 27 | |||
| Prior navitoclax | Y | 9 | 0.210 (0.03-1.59) | .095 |
| N | 53 | |||
CI, confidence interval; N, no; Y, yes.